Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04523428
Other study ID # HO159
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 23, 2020
Est. completion date December 2032

Study information

Verified date April 2023
Source Stichting Hemato-Oncologie voor Volwassenen Nederland
Contact A. Kater
Phone +31 20 5665785
Email a.p.kater@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of first-line treatment is the potential to retreat with venetoclax in patients who develop relapsed disease after a treatment free period. However, efficacy of venetoclax retreatment following a fixed duration venetoclax combination is still hypothetical as clinical data are lacking. Thus, there is an urgent need for data proving efficacy of venetoclax combinations following venetoclax treatment cessation. Testing of a novel venetoclax-containing regimen for relapsed CLL without the repeat of anti-CD20 monoclonal antibody (mAb) is a rational approach.


Description:

First-line venetoclax and CD20 antibody containing regimens that are currently being tested are based on either a fixed duration schedule or on an MRD-based time-limited schedule. The assumption of these regimens is that, aside from the deep (often uMRD) and often longstanding remissions, relapsed disease can be retreated with a venetoclax-based regimen. This, however, has not been formally proven. In this study, patients who received a first line regimen with either venetoclax and rituximab (GAIA/CLL13/HOVON 140 trial, [NCT02950051] ) or venetoclax and the second generation anti-CD20 antibody obinutuzumab (GAIA/CLL13/HOVON 140 trial, and the HOVON139 trial [Netherlands Trial Registry ID number #NTR6043]) and have relapsed with the need for a subsequent treatment are eligible to enter the study and to receive a combination of venetoclax with the highly selective BTK inhibitor acalabrutinib. Combination of venetoclax with acalabrutinib is expected to lead to uMRD, making discontinuation of therapy possible.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2032
Est. primary completion date December 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Documented CLL or SLL requiring treatment according to IWCLL criteria (appendix A) after at least (clinical) partial response as best response after the following initial study treatment: venetoclax-rituximab in HOVON 140/GAIA or venetoclax-obinutuzumab in HOVON 139/GIVE or HOVON 140/GAIA; - WHO/ECOG performance status 0-3 (appendix C), stage 3 only if attributable to CLL - Age at least 18 years; - Adequate BM function defined as: - Hemoglobin >5 mmol/l or Hb > 8 g/dL - Absolute neutrophil count (ANC) >0.75 x 109/L (750/µL), unless directly attributable to CLL infiltration of the BM, proven by BM biopsy - Platelet count >30 x 109/L (30,000/µL) without transfusion and irrespective whether it is attributable to CLL infiltration in the BM; - Estimated Glomerular Filtration Rate (eGFR) (MDRD) or estimated creatinine clearance (CrCl = 30ml/min (Cockcroft-Gault appendix E); Please note: in case eGFR or CrCl is <50ml/min the patient needs to be considered high risk for TLS - Adequate liver function as indicated: - Serum aspartate transaminase (ASAT) and alanine transaminase (ALAT) = 3.0 x upper limit of normal (ULN); - Bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin); - Prothrombin time (PT)/International normal ratio (INR) <1.5 x ULN and activated partial thromboplastin time (aPTT) <1.5 x ULN; - Negative serological testing for hepatitis B virus (HBV) (Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) negative) and hepatitis C virus (hepatitis C antibody). Subjects who are positive for anti-HBc or hepatitis C antibody may be included if they have a negative PCR within 6 weeks before enrollment. Those who are PCR positive will be excluded; Please note: For patients positive for anti-HBc HBV-DNA PCR has to be repeated every month until 12 months after last dose of study treatment. - Patient is able and willing to adhere to the study visit schedule and other protocol requirements; - Patient is capable of giving informed consent; - Written informed consent. Exclusion Criteria: - Any prior therapy with BTK inhibitor; - Prior treatment with venetoclax other than first line; - Other therapy with exception of chemo-/immunotherapy which is allowed also after venetoclax first line relapse; - Transformation of CLL (Richter's transformation); - Patient with a history of confirmed progressive multifocal leukoencephalopathy (PML); - Malignancies other than CLL currently requiring systemic therapy or not treated in curative intention or showing signs of progression after curative treatment; - Known allergy to xanthine oxidase inhibitors and/or rasburicase; - History of drug-specific hypersensitivity or anaphylaxis to any study drug (including active product or excipient components); - Active bleeding or history of bleeding diathesis (e.g. hemophilia or von Willebrand disease); - Active fungal, bacterial, and/or viral infection that requires systemic therapy; Please note: active controlled as well as chronic/recurrent infections are at risk of reactivation/infection during treatment; - Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection, auto-immune hemolysis, immune thrombocytopenia, diabetes, hypertension, hyperthyroidism or hypothyroidism etc.); - Patient known to be HIV-positive; - Patient requiring treatment with a strong cytochrome P450 (CYP) 3A inhibitor/inducer (see appendix J) or anticoagulant therapy with warfarin or phenoprocoumon or other vitamin K antagonists; Please note: Patients being treated with DOACs apixaban, edoxaban or rivaroxaban can be included, but must be properly informed about the potential risk of bleeding under treatment with acalabrutinib. (see appendix J) - History of stroke or intracranial hemorrhage within 6 months prior to registration; - Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease, myocardial infarction within 6 months) (CTCAE grade III-IV, see appendix D); - Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D); - Severe neurological or psychiatric disease (CTCAE grade III-IV, see appendix D); - Patient who has difficulty with or are unable to swallow oral medication, or have significant gastrointestinal disease that would limit absorption of oral medication; - Vaccination with live vaccines within 28 days prior to registration; - Use of any other experimental drug or therapy within 28 days of registration; - Major surgery within 28 days prior to registration; - Steroid therapy within 10 days prior to registration, with the exception of inhaled steroids for asthma, topical steroids, steroids up to 20 mg or dose equivalents of prednisolone daily to control autoimmune phenomenon's, or replacement/stress corticosteroids; - Pregnant women and nursing mothers; - Fertile men or women of childbearing potential unless: (1) surgically sterile or = 2 years after the onset of menopause; (2) willing to use a highly effective contraceptive method such as oral contraceptives, intrauterine device, sexual abstinence or combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) during study treatment and for 30 days after end of treatment; - Current participation in other clinical trial (other than follow up HOVON139/HOVON140); - Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Venetoclax/Acalabrutinib
All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.

Locations

Country Name City State
Belgium BE-Bruxelles-STLUC Brussels
Belgium BE-Leuven-UZLEUVEN Leuven
Denmark DK-Aarhus N-AUH Aarhus
Netherlands NL-Amsterdam-AMC Amsterdam
Netherlands NL-Arnhem-RIJNSTATE Arnhem
Netherlands NL-Breda-AMPHIA Breda
Netherlands NL-Delft-RDGG Delft
Netherlands NL-Den Bosch-JBZ Den Bosch
Netherlands NL-Dordrecht-ASZ Dordrecht
Netherlands NL-Ede-ZGV Ede
Netherlands NL-Eindhoven-MAXIMAMC Eindhoven
Netherlands NL-Groningen-UMCG Groningen
Netherlands NL-Leeuwarden-MCL Leeuwarden
Netherlands NL-Maastricht-MUMC Maastricht
Netherlands NL-Nieuwegein-ANTONIUS Nieuwegein
Netherlands NL-Rotterdam-IKAZIA Rotterdam
Netherlands NL-Rotterdam-MAASSTADZIEKENHUIS Rotterdam
Netherlands NL-Utrecht-UMCUTRECHT Utrecht

Sponsors (1)

Lead Sponsor Collaborator
Stichting Hemato-Oncologie voor Volwassenen Nederland

Countries where clinical trial is conducted

Belgium,  Denmark,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary uMRD in BM by flow cytometry after 26 cycles (2 acalabrutinib and 24 AV). To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and anti-CD20 mAb. 26 months
See also
  Status Clinical Trial Phase
Recruiting NCT05487651 - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies Phase 1
Recruiting NCT05590702 - French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings
Withdrawn NCT04660045 - Early Intervention With Acalabrutinib in Patients With High Risk CLL Phase 2
Recruiting NCT04215809 - Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL Phase 1
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1
Not yet recruiting NCT05975164 - the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
Withdrawn NCT05365100 - A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL Phase 1/Phase 2
Recruiting NCT04775745 - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Phase 1
Not yet recruiting NCT05918276 - Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL Phase 2
Recruiting NCT05920668 - Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
Recruiting NCT05269940 - A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05491044 - A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib Phase 2
Withdrawn NCT05176691 - HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Phase 1
Terminated NCT04149821 - Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy Phase 2
Withdrawn NCT04694560 - A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Recruiting NCT06104566 - Global Trial in APG2575 for Patients With CLL/SLL Phase 3
Recruiting NCT06319456 - A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Phase 3
Active, not recruiting NCT03493217 - A Study to Evaluate ICP-022 in Patients With CLL/ SLL Phase 1/Phase 2
Recruiting NCT05791409 - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL Phase 1/Phase 2